Dyne Therapeutics (NASDAQ:DYN) Stock Price Down 7.1% – What’s Next?

Dyne Therapeutics, Inc. (NASDAQ:DYN)’s share price dropped 7.1% during trading on Friday . The company traded as low as $27.80 and last traded at $28.16. Approximately 245,371 shares traded hands during trading, a decline of 84% from the average daily volume of 1,489,411 shares. The stock had previously closed at $30.31.

Analyst Upgrades and Downgrades

DYN has been the subject of a number of recent analyst reports. Piper Sandler restated an “overweight” rating and set a $53.00 target price on shares of Dyne Therapeutics in a report on Monday, September 23rd. Morgan Stanley upped their target price on Dyne Therapeutics from $48.00 to $52.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Stifel Nicolaus upped their target price on Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a report on Friday, August 16th. HC Wainwright restated a “buy” rating and set a $55.00 target price on shares of Dyne Therapeutics in a report on Wednesday. Finally, Chardan Capital restated a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a report on Wednesday. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $51.40.

Dyne Therapeutics Trading Down 5.4 %

The stock has a fifty day simple moving average of $32.58 and a 200-day simple moving average of $35.08. The company has a market capitalization of $2.92 billion, a PE ratio of -7.89 and a beta of 1.10.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.25). As a group, equities research analysts predict that Dyne Therapeutics, Inc. will post -3.02 EPS for the current year.

Insiders Place Their Bets

In other Dyne Therapeutics news, CEO John Cox purchased 32,000 shares of Dyne Therapeutics stock in a transaction on Wednesday, September 4th. The shares were bought at an average price of $33.04 per share, with a total value of $1,057,280.00. Following the purchase, the chief executive officer now directly owns 8,000 shares in the company, valued at $264,320. This trade represents a -133.33 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Dirk Kersten sold 79,411 shares of the stock in a transaction on Friday, September 20th. The stock was sold at an average price of $36.45, for a total value of $2,894,530.95. Following the transaction, the director now directly owns 234,127 shares in the company, valued at approximately $8,533,929.15. This represents a 25.33 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 158,975 shares of company stock worth $5,693,789. Company insiders own 20.77% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in DYN. RA Capital Management L.P. acquired a new stake in shares of Dyne Therapeutics during the 1st quarter worth $140,666,000. FMR LLC increased its holdings in shares of Dyne Therapeutics by 69.7% during the 3rd quarter. FMR LLC now owns 9,026,697 shares of the company’s stock worth $324,239,000 after buying an additional 3,707,734 shares during the last quarter. Janus Henderson Group PLC increased its holdings in shares of Dyne Therapeutics by 23,512.0% during the 1st quarter. Janus Henderson Group PLC now owns 2,675,240 shares of the company’s stock worth $75,915,000 after buying an additional 2,663,910 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Dyne Therapeutics by 8,284.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,132,092 shares of the company’s stock valued at $32,141,000 after purchasing an additional 1,118,590 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in Dyne Therapeutics by 47.7% in the 1st quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company’s stock valued at $97,669,000 after purchasing an additional 1,110,629 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.